The complex interplay between diabetes mellitus and atrial fibrillation

References

• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222.
   PubMed Web of Science ®Google Scholar
• National Diabetes Statistics Report | Diabetes | CDC [cited 2022 Jun 01]. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html.
   Google Scholar
• Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8(1):29.
   PubMed Web of Science ®Google Scholar
• Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J - Qual Care Clinl Outcomes. 2021;7(6):574–582.
   PubMed Web of Science ®Google Scholar
• Brundel BJJM, Ai X, Hills MT, et al. Atrial fibrillation. Nat Rev Dis Primers. 2022;8(1):21.
   PubMed Web of Science ®Google Scholar
• Echouffo-Tcheugui JB, Shrader P, Thomas L, et al., Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. J Am Coll Cardiol. 2017; 70(11): 1325–1335. .
   PubMed Web of Science ®Google Scholar
• Fumagalli S, Said SA, Laroche C, et al. Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):172–179.
   PubMed Web of Science ®Google Scholar
• Papazoglou AS, Kartas A, Samaras A, et al. Prognostic significance of diabetes mellitus in patients with atrial fibrillation. Cardiovasc Diabetol. 2021;20(1):40.
   PubMed Web of Science ®Google Scholar
• Karayiannides S, Lundman P, Friberg L, et al. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: A nationwide report. Diab Vasc Dis Res. 2018;15(1):31–38.
   PubMed Web of Science ®Google Scholar
• Domek M, Y-G L, Gumprecht J, et al One-year all-cause mortality risk among atrial fibrillation patients in Middle East with and without diabetes: The Gulf SAFE registry. Int J Cardiol. 2020;302:47–52.
   PubMed Web of Science ®Google Scholar
• Polovina M, Lund LH, Đikić D, et al. Type 2 diabetes increases the long‐term risk of heart failure and mortality in patients with atrial fibrillation. Eur J Heart Fail. 2020;22(1):113–125.
   PubMed Web of Science ®Google Scholar
• Anselmino M, Matta M, D’ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. Europace. 2015;17(10):1518–1525.
   PubMed Web of Science ®Google Scholar
• Staszewsky L, Cortesi L, Baviera M, et al. Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. Diabetes Res Clin Pract. 2015;109(3):476–484.
   PubMed Web of Science ®Google Scholar
• Marfella R, Sasso FC, Siniscalchi M, et al. Brief Episodes of Silent Atrial Fibrillation Predict Clinical Vascular Brain Disease in Type 2 Diabetic Patients. J Am Coll Cardiol. 2013;62(6):525–530.
   PubMed Web of Science ®Google Scholar
• Alwafi H, Wong ICK, Banerjee A, et al. Epidemiology and treatment of atrial fibrillation in patients with type 2 diabetes in the UK, 2001–2016. Sci Rep. 2020;10(1):12468.
   PubMedGoogle Scholar
• Gumprecht J, Lip GYH, Sokal A, et al. Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study. Cardiovasc Diabetol. 2021;20(1):128.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic Features of Chronic Atrial Fibrillation. N Engl J Med. 1982;306(17):1018–1022.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort. JAMA. 1994;271(11):840.
   PubMed Web of Science ®Google Scholar
• Pallisgaard JL, Schjerning A-M, Lindhardt TB, et al. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur J Prev Cardiol. 2016;23(6):621–627.
   PubMed Web of Science ®Google Scholar
• Alijla F, Buttia C, Reichlin T, et al. Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):230.
   PubMed Web of Science ®Google Scholar
• Huxley RR, Filion KB, Konety S, et al. Meta-Analysis of Cohort and Case–Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial Fibrillation. Am J Cardiol. 2011;108(1):56–62.
   PubMed Web of Science ®Google Scholar
• Aune D, Feng T, Schlesinger S, et al. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32(5):501–511.
   PubMed Web of Science ®Google Scholar
• Belbasis L, Mavrogiannis MC, Emfietzoglou M, et al, Environmental factors, serum biomarkers and risk of atrial fibrillation: an exposure-wide umbrella review of meta-analyses. Eur J Epidemiol. 2020; 35(3): 223–239.
   PubMed Web of Science ®Google Scholar
• Lind V, Hammar N, Lundman P, et al. Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure. Cardiovasc Diabetol. 2021;20(1):227.
   PubMed Web of Science ®Google Scholar
• Lee Y, Cha SJ, Park J-H, et al. Association between insulin resistance and risk of atrial fibrillation in non-diabetics. Eur J Prev Cardiol. 2020;27(18):1934–1941.
   PubMed Web of Science ®Google Scholar
• Lee Y-B, Han K, Kim B, et al. Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. Cardiovasc Diabetol. 2019;18(1):157.
   PubMed Web of Science ®Google Scholar
• Bisson A, Bodin A, Fauchier G, et al. Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovasc Diabetol. 2021;20(1):24.
   PubMed Web of Science ®Google Scholar
• Dahlqvist S, Rosengren A, Gudbjörnsdottir S, et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes Endocrinol. 2017;5(10):799–807.
   PubMed Web of Science ®Google Scholar
• Hallström S, Pivodic A, Rosengren A, et al. Risk Factors for Atrial Fibrillation in People With Type 1 Diabetes: An Observational Cohort Study of 36,258 Patients From the Swedish National Diabetes Registry. Diabetes Care. 2019;42(8):1530–1538.
   PubMed Web of Science ®Google Scholar
• Zethelius B, Gudbjörnsdottir S, Eliasson B, et al. Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia. 2015;58(10):2259–2268.
   PubMed Web of Science ®Google Scholar
• Kim J, Yang P-S, Park B-E, et al. Association of proteinuria and incident atrial fibrillation in patients with diabetes mellitus: a population-based senior cohort study. Sci Rep. 2021;11(1):17013.
   PubMed Web of Science ®Google Scholar
• Zhao H, Liu M, Chen Z, et al. Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. Chokesuwattanaskul R, editor. PLOS ONE. 2020;15(2):e0227262.
   PubMed Web of Science ®Google Scholar
• Lee S-R, Choi E-K, Rhee T-M, et al Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: A nationwide population-based study. Int J Cardiol. 2016;223:953–957.
   PubMed Web of Science ®Google Scholar
• Seyed Ahmadi S, Svensson A-M, Pivodic A, et al. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19(1):9.
   PubMed Web of Science ®Google Scholar
• Dublin S, Glazer NL, Smith NL, et al. Diabetes Mellitus, Glycemic Control, and Risk of Atrial Fibrillation. J Gen Intern Med. 2010;25(8):853–858.
   PubMed Web of Science ®Google Scholar
• Yang S, Choi E-K, Han K-D, et al. Risk of Atrial Fibrillation in Relation to the Time Course of Type 2 Diabetes Mellitus and Fasting Blood Glucose. Am J Cardiol. 2019;124(12):1881–1888.
   PubMed Web of Science ®Google Scholar
• S-H K, Park Y-M, Yun J-S, et al. Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: Nationwide population-based cohort study. J Diabetes Complications. 2018;32(2):157–163.
   PubMed Web of Science ®Google Scholar
• Hsu J-C, Yang -Y-Y, Chuang S-L, et al. Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):148.
   PubMed Web of Science ®Google Scholar
• Staerk L, Wang B, Preis SR, et al Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018;361:k1453.
   PubMed Web of Science ®Google Scholar
• Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477–486.
   PubMed Web of Science ®Google Scholar
• Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114(8):1217–1222.
   PubMed Web of Science ®Google Scholar
• Harati H, Zanetti D, Rao A, et al. No evidence of a causal association of type 2 diabetes and glucose metabolism with atrial fibrillation. Diabetologia. 2019;62(5):800–804.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu T, Ng CY, et al. Diabetes Mellitus and Atrial Remodeling: Mechanisms and Potential Upstream Therapies. Cardiovasc Ther. 2014;32(5):233–241.
   PubMed Web of Science ®Google Scholar
• Şerban RC, Scridon A. Data Linking Diabetes Mellitus and Atrial Fibrillation—How Strong Is the Evidence? From Epidemiology and Pathophysiology to Therapeutic Implications. Can J Cardiol. 2018;34(11):1492–1502.
   PubMed Web of Science ®Google Scholar
• Wang A, Green JB, Halperin JL, et al. Atrial Fibrillation and Diabetes Mellitus. J Am Coll Cardiol. 2019;74(8):1107–1115.
   PubMed Web of Science ®Google Scholar
• Bohne LJ, Johnson D, Rose RA, et al The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights. Front Physiol. 2019;10:10.
   PubMed Web of Science ®Google Scholar
• Lee T-W, Lee T-I, Lin Y-K, et al. Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies. Cell Mol Life Sci. 2021;78(3):923–934.
   PubMed Web of Science ®Google Scholar
• Bano A, Rodondi N, Beer JH, et al. Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study. J Am Heart Assoc. 2021;10(22).
   PubMed Web of Science ®Google Scholar
• Dei Cas A, Khan SS, Butler J, et al. Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. JACC Heart Fail. 2015;3(2):136–145.
   PubMed Web of Science ®Google Scholar
• Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124(1):121–141.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670–1690.
   PubMedGoogle Scholar
• Nichols GA, Reinier K, Chugh SS. Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation. Diabetes Care. 2009;32(10):1851–1856.
   PubMed Web of Science ®Google Scholar
• van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic Stiffness of the Failing Diabetic Heart. Circulation. 2008;117(1):43–51.
   PubMed Web of Science ®Google Scholar
• Jankauskas SS, Kansakar U, Varzideh F, et al. Heart failure in diabetes. Metabolism. 2021;125:154910.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461.
   PubMed Web of Science ®Google Scholar
• Hofer F, Pailer U, Sulzgruber P, et al. Relationship of diabetes, heart failure, and N‐terminal pro‐B‐type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. ESC Heart Fail. 2022;9(4):2367–2377.
   PubMed Web of Science ®Google Scholar
• Ganesan AN, Shipp NJ, Brooks AG, et al. Long‐term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta‐analysis. J Am Heart Assoc. 2013;2(2).
   PubMed Web of Science ®Google Scholar
• Bogossian H, Frommeyer G, Brachmann J, et al Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: Who benefits and who does not? Data from the German ablation registry. Int J Cardiol. 2016;214:25–30.
   PubMed Web of Science ®Google Scholar
• Creta A, Providência R, Adragão P, et al. Impact of Type-2 Diabetes Mellitus on the Outcomes of Catheter Ablation of Atrial Fibrillation (European Observational Multicentre Study). Am J Cardiol. 2020;125(6):901–906.
   PubMed Web of Science ®Google Scholar
• Ajjan RA, Kietsiriroje N, Badimon L, et al. Antithrombotic therapy in diabetes: which, when, and for how long?. Eur Heart J. 2021;42(23):2235–2259.
   PubMed Web of Science ®Google Scholar
• Carrizzo A, Izzo C, Oliveti M, et al. The Main Determinants of Diabetes Mellitus Vascular Complications: Endothelial Dysfunction and Platelet Hyperaggregation. Int J Mol Sci. 2018;19(10):2968.
   Web of Science ®Google Scholar
• Alzahrani S, Ajjan R. Review article: Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010;7(4):260–273.
   PubMed Web of Science ®Google Scholar
• Patti G, Cavallari I, Andreotti F, et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol. 2019;16(2):113–130.
   PubMed Web of Science ®Google Scholar
• Yosefy C, Pery M, Nevzorov R, et al. Difference in left atrial appendage remodeling between diabetic and nondiabetic patients with atrial fibrillation. Clin Cardiol. 2020;43(1):71–77.
   PubMed Web of Science ®Google Scholar
• Wei Y, Cui M, Liu S, et al. Increased hemoglobin A1c level associates with low left atrial appendage flow velocity in patients of atrial fibrillation. Nutr Metab Cardiovasc Dis. 2021;31(11):3176–3183.
   PubMed Web of Science ®Google Scholar
• Kezerle L, Tsadok MA, Akriv A, et al. Pre-Diabetes Increases Stroke Risk in Patients With Nonvalvular Atrial Fibrillation. J Am Coll Cardiol. 2021;77(7):875–884.
   PubMed Web of Science ®Google Scholar
• Overvad TF, Skjøth F, Lip GYH, et al. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. Stroke. 2015;46(8):2168–2174.
   PubMed Web of Science ®Google Scholar
• Ashburner JM, Go AS, Chang Y, et al. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients. J Am Coll Cardiol. 2016;67(3):239–247.
   PubMed Web of Science ®Google Scholar
• Chan Y-H, Chuang C, Chan -C-C, et al. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. Cardiovasc Diabetol. 2020;19(1):30.
   PubMed Web of Science ®Google Scholar
• Fangel MV, Nielsen PB, Kristensen JK, et al Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus. Circ Arrhythm Electrophysiol. 2019;12(5): 1–10.
   Web of Science ®Google Scholar
• v FM, Nielsen PB, Larsen TB, et al Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. Int J Cardiol. 2018;268:137–142.
   PubMed Web of Science ®Google Scholar
• Patti G, Lucerna M, Cavallari I, et al. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;69(4):409–419.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015;196:127–131.
   PubMed Web of Science ®Google Scholar
• Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4):675–682.e8.
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, Lewis BS, Lopes RD, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):86–94.
   PubMed Web of Science ®Google Scholar
• Plitt A, Ruff CT, Goudev A, et al. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2020;304:185–191.
   PubMed Web of Science ®Google Scholar
• Plitt A, Zelniker TA, Park J-G, et al, Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021; 7(FI1): f40–f49.
   PubMed Web of Science ®Google Scholar
• Cao B, Yao X, Zhang L, et al Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies. Mousa SA, editor. Cardiovasc Ther. 2021;2021:1–14.
   Google Scholar
• January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104–132.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 2021;42:373–498.
   Web of Science ®Google Scholar
• Newman JD, Vani AK, Aleman JO, et al. The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction. J Am Coll Cardiol. 2018;72(15):1856–1869.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Federal Register  Guidance for Industry on Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. [cited 2022 Jun 01]. Available from: https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic.
   Google Scholar
• Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569–589.
   PubMed Web of Science ®Google Scholar
• Nantsupawat T, Wongcharoen W, Chattipakorn SC, et al. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol. 2020;19(1):198.
   PubMed Web of Science ®Google Scholar
• Chang S-H, L-S W, Chiou M-J, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13(1):123.
   PubMedGoogle Scholar
• Deshmukh A, Ghannam M, Liang J, et al. Effect of metformin on outcomes of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32(5):1232–1239.
   PubMed Web of Science ®Google Scholar
• Ostropolets A, Elias PA, Reyes MV, et al Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas. Circ Arrhythm Electrophysiol. 2021;14(3):1–8.
   Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 [[cited 2022 May 26]];377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17:761–772.
   PubMed Web of Science ®Google Scholar
• Vrachatis DA, Papathanasiou KA, Iliodromitis KE, et al. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs. 2021;81:1381–1395.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Bonaca MP, Furtado RHM, et al, Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 2020; 141(15): 1227–1234. .
   PubMed Web of Science ®Google Scholar
• Li W, Chen X, Xu L, et al. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19(1):130.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
   PubMed Web of Science ®Google Scholar
• Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3(9):697–703.
   PubMed Web of Science ®Google Scholar
• Monami M, Nreu B, Scatena A, et al. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. J Endocrinol Invest. 2017;40(11):1251–1258.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou X, Kwong JSW, et al. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Sci Rep. 2017;7(1):1717.
   PubMedGoogle Scholar
• Chao T-F, Leu H-B, Huang -C-C, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol. 2012;156(2):199–202.
   PubMed Web of Science ®Google Scholar
• Pallisgaard JL, Lindhardt TB, Staerk L, et al Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2016;3:vw036.
   Web of Science ®Google Scholar
• Zhang Z, Zhang X, Korantzopoulos P, et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord. 2017;17(1):96
   PubMedGoogle Scholar
• Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642–653.
   PubMed Web of Science ®Google Scholar
• Chang C-Y, Yeh Y-H, Chan Y-H, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol. 2017;16(1):159.
   PubMedGoogle Scholar
• Ling AW-C, Chan -C-C, Chen S-W, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020;19(1):188.
   PubMed Web of Science ®Google Scholar
• Rados DV, Pinto LC, Remonti LR, et al. The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. Lehman R, editor. PLoS Med. 2016;13(4):e1001992.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Martens P-J, Vangoitsenhoven R. One hundred years of insulin therapy. Nat Rev Endocrinol. 2021;17(12):715–725.
   PubMed Web of Science ®Google Scholar
• Liou Y-S, Yang F-Y, Chen H-Y, et al. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. Taniyama Y, editor. PLOS ONE. 2018;13(8):e0197245.
   PubMed Web of Science ®Google Scholar
• Chen H-Y, Yang F-Y, Jong G-P, et al. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients. Eur J Clin Invest. 2017;47(5):388–393.
   PubMed Web of Science ®Google Scholar
• Mehta NK, Strickling J, Mark E, et al Beyond cardioversion, ablation and pharmacotherapies: Risk factors, lifestyle change and behavioral counseling strategies in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis. 2021;66:2–9.
   PubMed Web of Science ®Google Scholar
• O’Keefe EL, Sturgess JE, O’Keefe JH, et al Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification. Am J Cardiol. 2021;160:46–52.
   PubMed Web of Science ®Google Scholar
• Morin DP, Bernard ML, Madias C, et al. The State of the Art. Mayo Clin Proc. 2016;91(12):1778–1810.
   PubMed Web of Science ®Google Scholar
• Menezes AR, Lavie CJ, de Schutter A, et al Lifestyle Modification in the Prevention and Treatment of Atrial Fibrillation. Prog Cardiovasc Dis. 2015;58:117–125.
   PubMed Web of Science ®Google Scholar
• Wong CX, Sullivan T, Sun MT, et al. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation. JACC: Clinical Electrophysiology. 2015;1(3):139–152.
   PubMedGoogle Scholar
• Powell-Wiley TM, Poirier P, Burke LE, et al Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143:E984–E1010.
   PubMed Web of Science ®Google Scholar
• Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65(20):2159–2169.
   PubMed Web of Science ®Google Scholar
• Abed HS, Wittert GA, Leong DP, et al. Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation. JAMA. 2013;310(19):2050.
   PubMed Web of Science ®Google Scholar
• Grundvold I, Bodegard J, Nilsson PM, et al. Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. Cardiovasc Diabetol. 2015;14(1):5.
   PubMedGoogle Scholar
• Hsu J-C, Yang -Y-Y, Chuang S-L, et al. Underweight is a major risk factor for atrial fibrillation in Asian people with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):226.
   PubMedGoogle Scholar
• Alonso A, Bahnson JL, Gaussoin SA, et al. Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: The Look AHEAD randomized trial. Am Heart J. 2015;170(4):770–777.e5.
   PubMed Web of Science ®Google Scholar
• Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020;141(16):E750–E772.
   PubMed Web of Science ®Google Scholar
• Voskoboinik A, Kalman JM, de Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;382(1):20–28.
   PubMed Web of Science ®Google Scholar
• Choi Y, Han K-D, Choi E-K, et al. Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study. Diabetes Care. 2021;44(6):1393–1401.
   PubMed Web of Science ®Google Scholar
• Park CS, Han K-D, Choi E-K, et al. Lifestyle is associated with atrial fibrillation development in patients with type 2 diabetes mellitus. Sci Rep. 2021;11(1):4676
   PubMed Web of Science ®Google Scholar